How many carcinoid syndrome patients do you see? (symptomatic NETs)

Are you familiar with paltusotine (oral somatostatin agonist) and CAM2029 (subcutaneous octreotide)?

What percentage (%) of your patients with neuroendocrine tumors have symptomatic carcinoid syndrome?

What percentage (%) of your patients on SRLs have their symptoms well controlled?

What are the pros and cons of traditional long acting SRLs versus paltusotine versus CAM2029?

If paltusotine (oral somatostatin agonist) works as well as long acting octreotide/lanreotide on symptoms control, would you give it the benefit of the doubt that it prevents tumor progression?

• Yes
• No

Why or why not?

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your carcinoid syndrome patients currently on SRLs would you expect to switch to each treatment in 1, 3 and 5 years?

- I expect to switch % of patients to paltusotine:

• 1 year
• 3 years
• 5 years

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your carcinoid syndrome patients currently on SRLs would you expect to switch to each treatment in 1, 3 and 5 years?

- I expect to switch % of patients to CAM2029:

• 1 year
• 3 years
• 5 years

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your carcinoid syndrome patients currently on SRLs would you expect to switch to each treatment in 1, 3 and 5 years?

- I expect to keep % of patients on long acting SRLs:

• 1 year
• 3 years
• 5 years

Please explain your reasoning for your answers to the previous question.

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your treatment naive carcinoid syndrome patients would you start on each treatment in 1, 3 and 5 years?

- I expect to start % of patients to paltusotine:

• 1 year
• 3 years
• 5 years

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your treatment naive carcinoid syndrome patients would you start on each treatment in 1, 3 and 5 years?

- I expect to start % of patients to CAM2029:

• 1 year
• 3 years
• 5 years

If paltusotine is approved to control carcinoid symptoms (without long term PFS data), and CAM2029 is approved on PFS data, what percentage (%) of your treatment naive carcinoid syndrome patients would you start on each treatment in 1, 3 and 5 years?

- I expect to start % of patients on long acting SRLs:

• 1 year
• 3 years
• 5 years

Please explain your reasoning for your answers to the previous question.

Assuming approval of cabozantinib with a broad label in NET, what percentage (%) of r/r NET patients do you anticipate will receive cabozantinib?

Please explain your reasoning to the previous question.

Do you anticipate the phase 3 STELLAR-311 study of zanzalintinib vs everolimus for r/r NET will be successful?

• Yes
• No

Why or why not? Please explain your reasoning to the previous question.

Do you plan to use radioligand therapy as 1L therapy for your NET patients?

• Yes
• No

Why or why not? Please explain your reasoning to the previous question.

What percentage (%) of 2L NET patients receive radioligand therapy in your practice?

What is the biggest barrier to broader uptake of radioligand therapy at your center?

What is your favorite isotope for radioligand therapy and why?